-
1
-
-
67049162188
-
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
-
Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009;113:5412-7.
-
(2009)
Blood
, vol.113
, pp. 5412-5417
-
-
Landgren, O.1
Kyle, R.A.2
Pfeiffer, R.M.3
-
2
-
-
63849093676
-
Myeloma bone disease: recent advances in biology, diagnosis, and treatment
-
Sezer O. Myeloma bone disease: recent advances in biology, diagnosis, and treatment. Oncologist 2009;14:276-83.
-
(2009)
Oncologist
, vol.14
, pp. 276-283
-
-
Sezer, O.1
-
3
-
-
51649090583
-
Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma
-
Jakob C, Sterz J, Liebisch P, et al. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia 2008;22:1767-72.
-
(2008)
Leukemia
, vol.22
, pp. 1767-1772
-
-
Jakob, C.1
Sterz, J.2
Liebisch, P.3
-
4
-
-
43549108372
-
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma
-
Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008;80:490-4.
-
(2008)
Eur J Haematol
, vol.80
, pp. 490-494
-
-
Kaiser, M.1
Mieth, M.2
Liebisch, P.3
-
5
-
-
39449098165
-
Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA)
-
Hecht M, von Metzler I, Sack K, Kaiser M, Sezer O. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Exp Cell Res 2008;314:1082-93.
-
(2008)
Exp Cell Res
, vol.314
, pp. 1082-1093
-
-
Hecht, M.1
von Metzler, I.2
Sack, K.3
Kaiser, M.4
Sezer, O.5
-
6
-
-
74049162897
-
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
-
Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009;23:2210-21.
-
(2009)
Leukemia
, vol.23
, pp. 2210-2221
-
-
Fonseca, R.1
Bergsagel, P.L.2
Drach, J.3
-
7
-
-
41949130070
-
Improved survival in multiple myeloma and the impact of novel therapies
-
Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.
-
(2008)
Blood
, vol.111
, pp. 2516-2520
-
-
Kumar, S.K.1
Rajkumar, S.V.2
Dispenzieri, A.3
-
8
-
-
70350094381
-
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
-
Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009;23:1716-30.
-
(2009)
Leukemia
, vol.23
, pp. 1716-1730
-
-
Palumbo, A.1
Sezer, O.2
Kyle, R.3
-
9
-
-
34548133601
-
Bortezomib inhibits human osteoclastogenesis
-
von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007;21:2025-34.
-
(2007)
Leukemia
, vol.21
, pp. 2025-2034
-
-
von Metzler, I.1
Krebbel, H.2
Hecht, M.3
-
10
-
-
45749118333
-
The potential of proteasome inhibitors in cancer therapy
-
Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008;17:879-95.
-
(2008)
Expert Opin Investig Drugs
, vol.17
, pp. 879-895
-
-
Sterz, J.1
von Metzler, I.2
Hahne, J.C.3
Lamottke, B.4
Rademacher, J.5
Heider, U.6
Terpos, E.7
Sezer, O.8
-
11
-
-
58849160500
-
Heat shock protein 90 as a drug target: some like it hot
-
Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009;15:9-14.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 9-14
-
-
Banerji, U.1
-
12
-
-
77749270556
-
Hsp90 inhibitors: clinical development and future opportunities in oncology therapy
-
Gao Z, Garcia-Echeverria C, Jensen MR. Hsp90 inhibitors: clinical development and future opportunities in oncology therapy. Curr Opin Drug Discov Devel 2010;13:193-202.
-
(2010)
Curr Opin Drug Discov Devel
, vol.13
, pp. 193-202
-
-
Gao, Z.1
Garcia-Echeverria, C.2
Jensen, M.R.3
-
14
-
-
77949443606
-
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma
-
Kaiser M, Lamottke B, Mieth M, et al. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Eur J Haematol 2010;84:337-44.
-
(2010)
Eur J Haematol
, vol.84
, pp. 337-344
-
-
Kaiser, M.1
Lamottke, B.2
Mieth, M.3
-
16
-
-
0029824710
-
Nerve growth factor-mediated activation of the mitogen-activated protein (MAP) kinase cascade involves a signaling complex containing B-Raf and HSP90
-
Jaiswal RK, Weissinger E, Kolch W, Landreth GE. Nerve growth factor-mediated activation of the mitogen-activated protein (MAP) kinase cascade involves a signaling complex containing B-Raf and HSP90. J Biol Chem 1996;271:23626-9.
-
(1996)
J Biol Chem
, vol.271
, pp. 23626-23629
-
-
Jaiswal, R.K.1
Weissinger, E.2
Kolch, W.3
Landreth, G.E.4
-
17
-
-
0037131187
-
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function
-
Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002;277:39858-66.
-
(2002)
J Biol Chem
, vol.277
, pp. 39858-39866
-
-
Basso, A.D.1
Solit, D.B.2
Chiosis, G.3
Giri, B.4
Tsichlis, P.5
Rosen, N.6
-
18
-
-
0036187476
-
TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90
-
Chen G, Cao P, Goeddel DV. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell 2002;9:401-10.
-
(2002)
Mol Cell
, vol.9
, pp. 401-410
-
-
Chen, G.1
Cao, P.2
Goeddel, D.V.3
-
19
-
-
1542298267
-
Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone
-
Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004;206:149-57.
-
(2004)
Cancer Lett
, vol.206
, pp. 149-157
-
-
Workman, P.1
-
20
-
-
20144375312
-
Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors
-
Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1885-1893
-
-
Grem, J.L.1
Morrison, G.2
Guo, X.D.3
-
21
-
-
84859622377
-
-
inventors; Novartis Pharma AG, assignee. 2-amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidin-5-one compounds. US patent 20070123546. 2007 May 31
-
Machajewski T, Shafer C, McBride C, inventors; Novartis Pharma AG, assignee. 2-amino-7, 8-dihydro-6H-pyrido[4, 3-D]pyrimidin-5-one compounds. US patent 20070123546. 2007 May 31.
-
-
-
Machajewski, T.1
Shafer, C.2
McBride, C.3
-
22
-
-
79961013560
-
Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease
-
Labbadia J, Cunliffe H, Weiss A, et al. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J Clin Invest 2011;121:3306-19.
-
(2011)
J Clin Invest
, vol.121
, pp. 3306-3319
-
-
Labbadia, J.1
Cunliffe, H.2
Weiss, A.3
-
23
-
-
33644554220
-
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma
-
Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, Sezer O, Heider U. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 2006;91:248-51.
-
(2006)
Haematologica
, vol.91
, pp. 248-251
-
-
Kaiser, M.1
Zavrski, I.2
Sterz, J.3
Jakob, C.4
Fleissner, C.5
Kloetzel, P.M.6
Sezer, O.7
Heider, U.8
-
24
-
-
0021118703
-
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
-
Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
-
(1984)
Adv Enzyme Regul
, vol.22
, pp. 27-55
-
-
Chou, T.C.1
Talalay, P.2
-
25
-
-
79952270884
-
HDACs link the DNA damage response, processing of double-strand breaks and autophagy
-
Robert T, Vanoli F, Chiolo I, et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 2011;471:74-9.
-
(2011)
Nature
, vol.471
, pp. 74-79
-
-
Robert, T.1
Vanoli, F.2
Chiolo, I.3
-
26
-
-
49449105426
-
Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
-
Stuhmer T, Zollinger A, Siegmund D, et al. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 2008;22:1604-12.
-
(2008)
Leukemia
, vol.22
, pp. 1604-1612
-
-
Stuhmer, T.1
Zollinger, A.2
Siegmund, D.3
-
27
-
-
80053948169
-
Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma
-
Khong T, Spencer A. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther 2011;10:1909-17.
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 1909-1917
-
-
Khong, T.1
Spencer, A.2
-
28
-
-
17144377442
-
Hsp90 activation and cell cycle regulation
-
Burrows F, Zhang H, Kamal A. Hsp90 activation and cell cycle regulation. Cell Cycle 2004;3:1530-6.
-
(2004)
Cell Cycle
, vol.3
, pp. 1530-1536
-
-
Burrows, F.1
Zhang, H.2
Kamal, A.3
-
29
-
-
69449095860
-
Caspases and kinases in a death grip
-
Kurokawa M, Kornbluth S. Caspases and kinases in a death grip. Cell 2009;138:838-54.
-
(2009)
Cell
, vol.138
, pp. 838-854
-
-
Kurokawa, M.1
Kornbluth, S.2
-
30
-
-
50449086728
-
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
-
San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
-
(2008)
N Engl J Med
, vol.359
, pp. 906-917
-
-
San Miguel, J.F.1
Schlag, R.2
Khuageva, N.K.3
-
31
-
-
57649158485
-
Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment
-
Heider U, Kaiser M, Mieth M, et al. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 2009;82:31-8.
-
(2009)
Eur J Haematol
, vol.82
, pp. 31-38
-
-
Heider, U.1
Kaiser, M.2
Mieth, M.3
-
32
-
-
73349115580
-
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma
-
Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009;27:5713-9.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5713-5719
-
-
Richardson, P.G.1
Weller, E.2
Jagannath, S.3
-
33
-
-
82155178738
-
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma
-
Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011;118:5752-8.
-
(2011)
Blood
, vol.118
, pp. 5752-5758
-
-
Moreau, P.1
Avet-Loiseau, H.2
Facon, T.3
-
34
-
-
70549097114
-
Caspase 2 in apoptosis, the DNA damage response and tumour suppression: enigma no more?
-
Kumar S. Caspase 2 in apoptosis, the DNA damage response and tumour suppression: enigma no more? Nat Rev Cancer 2009;9:897-903.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 897-903
-
-
Kumar, S.1
|